SB 202190 hydrochloride 15811 InChi: InChI=1S/C25H39N3O6S/c1-16(2)14-19(22(30)27-20(23(31)32)15-17-10-8-7-9-11-17)26-21(29)18(12-13-35-6)28-24(33)34-25(3

InChi: InChI=1S/C25H39N3O6S/c1-16(2)14-19(22(30)27-20(23(31)32)15-17-10-8-7-9-11-17)26-21(29)18(12-13-35-6)28-24(33)34-25(3

InChi: InChI=1S/C14H23NO

PF-03491390

indicating the decrease of the subsequent NEDD8-UBC12 complex

InChi: InChI=1S/C17H14O6/c1-21-14-8-13-15(16(20)17(14)22-2)11(19)7-12(23-13)9-3-5-10(18)6-4-9/h3-8

SB 202190 hydrochloride 15811 InChi: InChI=1S/C25H39N3O6S/c1-16(2)14-19(22(30)27-20(23(31)32)15-17-10-8-7-9-11-17)26-21(29)18(12-13-35-6)28-24(33)34-25(3SB 202190 hydrochloride is an inhibitor of p38 MAP kinases, inhibiting p38 (SAPK2A, MAPK14) and p38 (SAPK2B, MAPK11). It directly binds to the ATP binding pocket of p38 MAP kinases and has been used to elucidate the roles of p38 MAP kinases in inflammatory cytokine expression, nicotine induced receptor expression, and HIV mediated depressive disorder. SB 202190 hydrochloride is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for